Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Donor-Derived DNA Testing May Reduce Biopsies in Kidney Transplant Monitoring

By LabMedica International staff writers
Posted on 29 Oct 2026

Kidney transplant recipients require ongoing monitoring for rejection and graft injury, but biopsy-based assessment can be complicated by invasive surveillance procedures and ambiguous findings. More...

These limitations can make treatment decisions more difficult. New clinical data now link a donor-derived cell-free DNA diagnostic approach with adverse graft outcomes while also showing potential to reduce the need for biopsy in kidney transplant monitoring.

CareDx (Brisbane, CA, USA) presented results for AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) at the American Society of Nephrology (ASN) Kidney Week 2026, held October 22–25 in Denver. The data address challenges including the significance of borderline biopsy findings, reliance on invasive surveillance biopsies, and rejection prediction as diagnostic criteria evolve. AlloSure Plus was also evaluated as a model that incorporates clinical parameters in addition to AlloSure results.

AlloSure Kidney measures donor-derived cell-free DNA (dd-cfDNA) to assess graft injury, while AlloSure Plus combines the AlloSure result with additional clinical parameters. In the latest Kidney Allograft Outcomes AlloSure Registry (KOAR) analysis, 131 kidney transplant recipients with biopsy-proven borderline changes or T-cell-mediated rejection (TCMR) had AlloSure Kidney testing within 30 days before biopsy. An AlloSure Kidney level of at least 1% was independently associated with a nearly threefold higher risk of allograft loss or a decline in kidney function of at least 30% (P=0.002).

A separate multinational randomized trial conducted by the Paris Transplant Group evaluated 332 kidney transplant recipients across seven centers in four European countries between months 3 and 12 after transplantation. Patients monitored with dd-cfDNA underwent 49% fewer biopsies than those managed with surveillance biopsies, corresponding to an incidence rate ratio of 0.51 (P<0.001). Safety outcomes were similar between the groups, including death or graft loss at 7.1% versus 6.1%, biopsy-proven acute rejection at 7.1% versus 7.3%, and kidney function at 12 months.

The Paris Transplant Group also conducted an extended validation study involving 4,976 kidney transplant recipients and 6,827 biopsies from 29 centers across four continents. Under the updated Banff 2024 pathology criteria, AlloSure Kidney and AlloSure Plus maintained strong performance for predicting rejection, with an area under the curve of 0.833. Together, the findings support the potential role of dd-cfDNA monitoring in identifying patients with borderline changes or TCMR who are at greater risk of adverse graft outcomes while reducing reliance on routine biopsy surveillance.

“For decades, biopsy has been the reference standard for assessing rejection, despite being invasive; resulting in inconvenience, risk and stress for patients; and being resource-intensive for transplant programs,” said Dr. Jeffrey Teuteberg, Chief Medical Officer of CareDx. 

“These data show how AlloSure Kidney can provide clinically meaningful information across several of the most difficult decisions in kidney transplant care, from identifying risk when biopsy findings are ambiguous to enabling a less invasive approach to monitoring. Combined with the long-term outcome data presented at this year’s ATC, the evidence increasingly supports the use of AlloSure Kidney to help clinicians assess risk and guide patient management,” added Dr. Teuteberg.

Related Links
CareDx


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.